A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB)
Authors
Paplomata, EBachelot, T
Mueller, V
Murias, C
Murthy, RK
Okines, AFC
Wardley, Andrew M
Walker, LN
Oliveira, AMAD
Affiliation
Department of Hematology and Medical Oncology, Emory Winship Cancer Institute Atlanta, GA,Issue Date
2019
Metadata
Show full item recordCitation
Paplomata E, Bachelot T, Mueller V, Murias C, Murthy RK, Okines AFC, et al. 198TiP A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB). Ann Oncol. 2019;30(Supplement_3):63-4.Journal
Annals of OncologyDOI
10.1093/annonc/mdz100.049Additional Links
https://dx.doi.org/10.1093/annonc/mdz100.049Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdz100.049